

OFFICE OF HUMAN RESEARCH PROTECTION PROGRAMME
(OHRPP)

**10. DSRB REVIEW OUTCOMES &
ADDITIONAL REMINDERS
BIOMEDICAL DOMAINS A-E
&
POPULATION HEALTH – DOMAIN F**

Reference:

NHG Investigator Manual


NHG Group Research

Version November 2022




Adding years of healthy life


Overview of DSRB Review Outcomes



Triage & Review Processes




DSRB Review Outcomes – Expedited/ Exempt Reviews




- Approved as submitted.
- Expiry Date: 1 year from date when approval was granted (i.e. 1 year from Full Board meeting date).

Approval process:
Outcome by one domain is recognised by all domains.

DSRB Review Outcomes – For Full Board Reviews




DSRB Review Outcomes



- Significant issues identified, or substantial modifications required to study protocol.
- Proposal may be sent to an Independent Consultant for further review.
- PI's responses / amendments will be reviewed at the next full board meeting.
- PI may be invited to attend the full board meeting to clarify issues.
- Approval date of study will be advised by DSRB secretariat.

Approval process:
Outcome by one domain is recognized by all domains.

DSRB Review Outcomes



- The proposal fails to meet one or more criteria used by the DSRB for approval of research.
- Disapproval cannot be given through the expedited review mechanism and may only be given by majority vote at a convened meeting of the DSRB.
- PI may invoke appeal process (email respective Secretariat for assistance).

Approval process:
Outcome by one domain is recognized by all domains.

Additional Reminders

1. A **Clinical Trial Certificate (CTC) / Clinical Trial Authorization (CTA)** is required for studies:
 - Investigating the use of locally unregistered therapeutic products.
 - Investigating locally registered therapeutic products not used in accordance with approved product labelling.
 - Involving healthy volunteers.
2. A **Clinical Trial Notification (CTN)** is required for studies investigating the use of locally registered therapeutic products used in accordance with product label. DSRB approval is required prior to HSA application.
 - Application to the **Health Sciences Authority (HSA)** via PRISM.
 - Post-approval reporting obligations apply, e.g. serious breaches, adverse event reports, etc.

For more details on CTC/CTA/CTC, please refer to <https://www.hsa.gov.sg> > Clinical Trials > Regulatory overview of clinical trials

3. MOH approval should be obtained if the study is restricted HBR. Application of MOH approval needs to be submitted via **TIARAS**

For more details on restricted HBR and TIARAS, please refer to <https://www.moh.gov.sg> > Legislation > Human Biomedical Research Act.

Questions?

Refer to www.research.nhg.com.sg

Or contact the NHG Research
Education Unit @
researchcoord@nhg.com.sg